Anna Mowry bought $11k of NAUT
CFO and Treasurer at Nautilus Biotechnology, Inc.. 15,000 shares at an average of $0.77, traded May 29, 2025, filed Jun 2, 2025.
Score components
- +22RoleCFO
- 0Trade size$11k at market
- +6Relative to holdingsHoldings up 22%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001808805-25-000051, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 29, 2025 | POpen-market purchase Common Stock | +15,000 | $0.77 | $11k | 83,000 | Jun 2, 2025 |
Related signals
Other insiders at Nautilus Biotechnology, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 23Weak | NAUTbuy Nautilus Biotechnology, Inc. | Kentaro Suzuki Chief Marketing Officer | $5,960 4,000 shares | - | |
| 44Moderate | Nautilus Biotechnology, Inc. | Sujal M Patel CEO, President, and Secretary | $136k 200,000 shares | +2% | |
| 29Weak | Nautilus Biotechnology, Inc. | Matthew B. Murphy General Counsel | $13k 20,000 shares | +37% | |
| 10Weak | NAUTbuy Nautilus Biotechnology, Inc. | Parag Mallick Chief Scientist | $9,885 13,500 shares | +0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.